Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells

作者：Yan-Ruide Li, Zhe Li, Yichen Zhu, Miao Li, Yuning Chen, Derek Lee, Christopher J Ochoa, Tanya Singh, Gabriella DiBernardo, Wenbin Guo, Shuo Li, Yang Zhou, Yanqi Yu, Adam B. Kramer, Matthew Wilson, Kuangyi Zhou, Zachary Spencer Dunn, Ying Fang, Jiaji Yu, Yu Jeong Kim, Jie Huang, Xinyuan Shen, Yu-Chen Wang, Ryan Hon, Taylor Basso, Evelynn Chen, Enbo Zhu, Siyu Lin, Adam Neal, Neda A. Moatamed, Scott Oh, Saeed Sadeghi, Calvin Q. Pan, Aijun Wang, Aldons J. Lusis, Xianghong Jasmine Zhou, Jin Zhou, Matteo Pellegrini, Pin Wang, Sanaz Memarzadeh, Lili Yang · 发表于：Med · 年份：2025 · DOI：10.1016/j.medj.2025.100804 · 被引用次数：41 · 研究领域：CAR-T cell therapy research、Immune Cell Function and Interaction、Transgenic Plants and Applications

BACKGROUND: Ovarian cancer (OC) poses a significant challenge for conventional chimeric antigen receptor-engineered T (CAR-T) cell therapy, due to frequent recurrence linked to tumor heterogeneity, platinum resistance, immune evasion, and an immunosuppressive tumor microenvironment (TME). METHODS: CAR-NKT cells at high yield and purity. FINDINGS: CAR-NKT cells also exhibit a high safety profile with reduced cytokine release syndrome. Additionally, these cells do not induce graft-versus-host disease and resist host immune-cell-mediated allorejection. CONCLUSIONS: CAR-NKT cell therapy for OC. FUNDING: Major funding was provided by the California Institute for Regenerative Medicine (CIRM).